Biodelivery Sci Intl (BDSI) 2.41 $BDSI
BioDelivery Sciences to Host Conference Call and Webcast of Second Quarter 2016 Results on Tuesday, August 9
PR Newswire - Mon Aug 01, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will host a conference call and webcast on Tuesday, August 9, at 8:00 A.M. Eastern time. During the call, management will review BDSI's second quarter 2016 financial results and provide a business update.
BDSI: 2.41 (-0.14)
BioDelivery Sciences (BDSI) Catches Eye: Stock Rises 12%
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:15AM CDT
BioDelivery Sciences International, Inc.(BDSI) shares rose 12% on the day.
MACK: 5.82 (+0.02), BDSI: 2.41 (-0.14)
Trending Stocks This Week
ACCESSWIRE - Wed Jul 13, 7:04AM CDT
NEW YORK, NY / ACCESSWIRE / July 13, 2016 / The Stock Expert is issuing an alert on these four companies - Medovex Corp. (MDVX) SemiLEDs Corporation (LEDS), BioDelivery Sciences International, Inc. (BDSI) and Sage Therapeutics, Inc. (SAGE) should be on your watch list this week.
BDSI: 2.41 (-0.14), SAGE: 44.10 (-0.76), LEDS: 5.49 (-0.11), MDVX: 1.34 (-0.02)
BioDelivery Sciences Announces the Securing of Preferred Formulary Status for BUNAVAIL on a Significant Managed Care Plan
PR Newswire - Mon Jul 11, 3:01PM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced it has signed an agreement with a significant managed care provider providing preferred access to BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) for the maintenance treatment of opioid dependence.
BDSI: 2.41 (-0.14)
Endo's (ENDP) Pain Drug Opana ER to Face FDA Panel in Fall
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:47AM CDT
Endo International's (ENDP) pain drug is expected to come before the FDA's Advisory Committee this fall and hence the FDA will not render its decision by Jul 29.
BDSI: 2.41 (-0.14), ENDP: 16.88 (-0.48), ANIP: 61.06 (+0.46), BMY: 76.19 (+1.38)
BioDelivery Sciences to Present at the William Blair Annual Growth Stock Conference
PR Newswire - Wed Jun 08, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will present at the William Blair Annual Growth Stock Conference. The presentation, which will be webcast, is scheduled for Wednesday, June 15, 2016, at 11:40 AM Eastern Time at the Four Seasons Hotel in Chicago.
BDSI: 2.41 (-0.14)
BioDelivery Sciences Announces Presentation of Data on the Impact of a State Formulary Conversion to BUNAVAIL® at the International Conference on Opioids
PR Newswire - Mon Jun 06, 10:48AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the presentation of data today at the 5th International Conference on Opioids (ICOO 2016), which takes place June 5-7, 2016 in Boston, Massachusetts. The poster is being presented by Dr. Richard Soper, Chief, Addiction Medicine & Chair, Board of Directors, Center for Behavioral Wellness, Nashville, Tennessee, who is lead author.
BDSI: 2.41 (-0.14)
New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA(TM) (Buprenorphine) Buccal Film For Chronic Pain
PR Newswire Europe - Fri Jun 03, 7:00AM CDT
Findings also show sustained pain relief with BELBUCA(TM) treatment for up to 48 weeks among chronic pain sufferers who require around-the-clock pain relief
BDSI: 2.41 (-0.14), ENDP: 16.88 (-0.48), ENL.TO: 22.85 (-0.82)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.41 (-0.14), INSY: 15.91 (+0.26), AGIO: 45.69 (+0.46), GNCA: 4.00 (-0.07)
BioDelivery Sciences to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference. The presentation, which will be webcast, is scheduled for Wednesday, June 8, 2016, at 11:00 AM Eastern Time at the Grand Hyatt in New York City.
BDSI: 2.41 (-0.14)
BioDelivery-Collegium Collaborate for Onsolis in U.S.
Zacks Equity Research - Zacks Investment Research - Thu May 12, 4:34PM CDT
BioDelivery Sciences (BDSI) and Collegium Pharmaceutical, have entered into a licensing deal for Onsolis in the U.S.
BDSI: 2.41 (-0.14), HSKA: 43.41 (+0.86), ANIP: 61.06 (+0.46), COLL: 11.86 (-0.27)
Downgrade Alert for BioDelivery Sciences (BDSI)
Comtex SmarTrend(R) - Thu May 12, 3:09AM CDT
BioDelivery Sciences (NASDAQ:BDSI) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $2.18 on volume of 1.6 million shares, above average daily volume of 1.2 million. In the past 52 weeks, shares of BioDelivery Sciences have traded between a low of $1.91 and a high of $9.91 and closed yesterday at $2.18, which is 14% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 2.6% while the 200-day MA has slid 2.5%.
BDSI: 2.41 (-0.14)
Collegium Licenses the U.S. rights to ONSOLIS(R) from BioDelivery Sciences
GlobeNewswire - Wed May 11, 3:05PM CDT
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the licensing of the U.S. rights to develop and commercialize ONSOLIS (fentanyl buccal soluble film) from BioDelivery Sciences International, Inc. (Nasdaq:BDSI). Collegium expects to launch the product in mid-2017.
BDSI: 2.41 (-0.14), COLL: 11.86 (-0.27)
BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a Licensing Agreement for ONSOLIS® in the U.S.
PR Newswire - Wed May 11, 3:05PM CDT
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the signing of a licensing agreement under which BDSI is granting the exclusive rights to develop and commercialize ONSOLIS® (fentanyl buccal soluble film) in the U.S. to Collegium.
BDSI: 2.41 (-0.14), COLL: 11.86 (-0.27)
BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.41 (-0.14), ENDP: 16.88 (-0.48), BSTC: 40.32 (-0.18), ARQL: 1.68 (+0.02)
BioDelivery's (BDSI) Q1 Loss in Line with Expectation
Zacks Equity Research - Zacks Investment Research - Tue May 10, 7:50AM CDT
BioDelivery's first-quarter 2016 loss of 36 cents per share came in line with consensus estimates.
BDSI: 2.41 (-0.14)
BioDelivery Sciences Provides Corporate Update and Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:00AM CDT
-- Strategic initiatives implemented to better align BUNAVAIL® expenses with revenue as part of ongoing efforts to preserve and enhance long-term value; changes expected to result in savings of approximately $20 million through 2017
BDSI: 2.41 (-0.14)
BioDelivery Sciences to Host Conference Call and Webcast of Second Quarter 2016 Results on Tuesday, August 9
PR Newswire - Mon Aug 01, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will host a conference call and webcast on Tuesday, August 9, at 8:00 A.M. Eastern time. During the call, management will review BDSI's second quarter 2016 financial results and provide a business update.
BDSI: 2.41 (-0.14)
BioDelivery Sciences (BDSI) Catches Eye: Stock Rises 12%
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 7:15AM CDT
BioDelivery Sciences International, Inc.(BDSI) shares rose 12% on the day.
MACK: 5.82 (+0.02), BDSI: 2.41 (-0.14)
Trending Stocks This Week
ACCESSWIRE - Wed Jul 13, 7:04AM CDT
NEW YORK, NY / ACCESSWIRE / July 13, 2016 / The Stock Expert is issuing an alert on these four companies - Medovex Corp. (MDVX) SemiLEDs Corporation (LEDS), BioDelivery Sciences International, Inc. (BDSI) and Sage Therapeutics, Inc. (SAGE) should be on your watch list this week.
BDSI: 2.41 (-0.14), SAGE: 44.10 (-0.76), LEDS: 5.49 (-0.11), MDVX: 1.34 (-0.02)
BioDelivery Sciences Announces the Securing of Preferred Formulary Status for BUNAVAIL on a Significant Managed Care Plan
PR Newswire - Mon Jul 11, 3:01PM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced it has signed an agreement with a significant managed care provider providing preferred access to BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) for the maintenance treatment of opioid dependence.
BDSI: 2.41 (-0.14)
Endo's (ENDP) Pain Drug Opana ER to Face FDA Panel in Fall
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:47AM CDT
Endo International's (ENDP) pain drug is expected to come before the FDA's Advisory Committee this fall and hence the FDA will not render its decision by Jul 29.
BDSI: 2.41 (-0.14), ENDP: 16.88 (-0.48), ANIP: 61.06 (+0.46), BMY: 76.19 (+1.38)
BioDelivery Sciences to Present at the William Blair Annual Growth Stock Conference
PR Newswire - Wed Jun 08, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will present at the William Blair Annual Growth Stock Conference. The presentation, which will be webcast, is scheduled for Wednesday, June 15, 2016, at 11:40 AM Eastern Time at the Four Seasons Hotel in Chicago.
BDSI: 2.41 (-0.14)
BioDelivery Sciences Announces Presentation of Data on the Impact of a State Formulary Conversion to BUNAVAIL® at the International Conference on Opioids
PR Newswire - Mon Jun 06, 10:48AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the presentation of data today at the 5th International Conference on Opioids (ICOO 2016), which takes place June 5-7, 2016 in Boston, Massachusetts. The poster is being presented by Dr. Richard Soper, Chief, Addiction Medicine & Chair, Board of Directors, Center for Behavioral Wellness, Nashville, Tennessee, who is lead author.
BDSI: 2.41 (-0.14)
New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA(TM) (Buprenorphine) Buccal Film For Chronic Pain
PR Newswire Europe - Fri Jun 03, 7:00AM CDT
Findings also show sustained pain relief with BELBUCA(TM) treatment for up to 48 weeks among chronic pain sufferers who require around-the-clock pain relief
BDSI: 2.41 (-0.14), ENDP: 16.88 (-0.48), ENL.TO: 22.85 (-0.82)
What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.41 (-0.14), INSY: 15.91 (+0.26), AGIO: 45.69 (+0.46), GNCA: 4.00 (-0.07)
BioDelivery Sciences to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:00AM CDT
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference. The presentation, which will be webcast, is scheduled for Wednesday, June 8, 2016, at 11:00 AM Eastern Time at the Grand Hyatt in New York City.
BDSI: 2.41 (-0.14)
BioDelivery-Collegium Collaborate for Onsolis in U.S.
Zacks Equity Research - Zacks Investment Research - Thu May 12, 4:34PM CDT
BioDelivery Sciences (BDSI) and Collegium Pharmaceutical, have entered into a licensing deal for Onsolis in the U.S.
BDSI: 2.41 (-0.14), HSKA: 43.41 (+0.86), ANIP: 61.06 (+0.46), COLL: 11.86 (-0.27)
Downgrade Alert for BioDelivery Sciences (BDSI)
Comtex SmarTrend(R) - Thu May 12, 3:09AM CDT
BioDelivery Sciences (NASDAQ:BDSI) was downgraded from Buy to Hold at Cantor today. The stock closed yesterday at $2.18 on volume of 1.6 million shares, above average daily volume of 1.2 million. In the past 52 weeks, shares of BioDelivery Sciences have traded between a low of $1.91 and a high of $9.91 and closed yesterday at $2.18, which is 14% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 2.6% while the 200-day MA has slid 2.5%.
BDSI: 2.41 (-0.14)
Collegium Licenses the U.S. rights to ONSOLIS(R) from BioDelivery Sciences
GlobeNewswire - Wed May 11, 3:05PM CDT
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the licensing of the U.S. rights to develop and commercialize ONSOLIS (fentanyl buccal soluble film) from BioDelivery Sciences International, Inc. (Nasdaq:BDSI). Collegium expects to launch the product in mid-2017.
BDSI: 2.41 (-0.14), COLL: 11.86 (-0.27)
BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a Licensing Agreement for ONSOLIS® in the U.S.
PR Newswire - Wed May 11, 3:05PM CDT
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the signing of a licensing agreement under which BDSI is granting the exclusive rights to develop and commercialize ONSOLIS® (fentanyl buccal soluble film) in the U.S. to Collegium.
BDSI: 2.41 (-0.14), COLL: 11.86 (-0.27)
BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.41 (-0.14), ENDP: 16.88 (-0.48), BSTC: 40.32 (-0.18), ARQL: 1.68 (+0.02)
BioDelivery's (BDSI) Q1 Loss in Line with Expectation
Zacks Equity Research - Zacks Investment Research - Tue May 10, 7:50AM CDT
BioDelivery's first-quarter 2016 loss of 36 cents per share came in line with consensus estimates.
BDSI: 2.41 (-0.14)
BioDelivery Sciences Provides Corporate Update and Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:00AM CDT
-- Strategic initiatives implemented to better align BUNAVAIL® expenses with revenue as part of ongoing efforts to preserve and enhance long-term value; changes expected to result in savings of approximately $20 million through 2017
BDSI: 2.41 (-0.14)
